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Abstract
Introduction Hyperlactatemia is frequent in critically ill patients
and is often used as a marker of adverse outcome. However,
studies to date have focused on selected intensive care unit
(ICU) populations. We sought to determine the occurrence and
relation of hyperlactatemia with ICU mortality in all patients
admitted to four ICUs in a large regional critical care system.
Methods All adults ([greater than or equal to] 18 years)
admitted to ICUs in the Calgary Health Region (population 1.2
million) during 2003 to 2006 were included retrospectively.
Lactate determinations were at the discretion of the attending
service and hyperlactatemia was defined by a lactate level > 2
mmol/L.
Results A total of 13,932 ICU admissions occurred among
11,581 patients. The median age was 63 years (37% female),
the mean APACHE II score was 25 ± 9 (n = 13,922). At
presentation (within first day of admission), 12,246 patients had
at least one lactate determination and the median peak lactate
was 1.8 (IQR 1.2 to 2.9) mmol/L. The cumulative incidence of at
least one documented episode of hyperlactatemia was 5578/
13,932 (40%); 5058 (36%) patients had hyperlactatemia at
presentation, and a further 520 (4%) developed hyperlactatemia
subsequently. The incidence of hyperlactatemia varied
significantly by major admitting diagnostic category (P < 0.001)
and was highest among neuro/trauma patients 1053/2328
(45%), followed by medical 2047/4935 (41%), other surgical
900/2274 (40%), and cardiac surgical 1578/4395 (36%).
Among a cohort of 9107 first admissions with ICU stay of at
least one day, both hyperlactatemia at presentation (712/3634
(20%) vs. 289/5473 (5%); P < 0.001) and its later development
(101/379 (27%) vs. 188/5094 (4%); P  < 0.001) were
associated with significantly increased case fatality rates as
compared with patients without elevated lactate. After
controlling for confounding effects in multivariable logistic
regression analysis, hyperlactatemia was an independent risk
factor for death.
Conclusions Hyperlactatemia is common among the critically ill
and predicts risk for death.
Introduction
Elevations of blood lactate are common in patients admitted to
the intensive care unit (ICU) and have been associated with
adverse outcomes [1-7]. Early studies suggested that venous
lactate levels on admission to medical ICUs in patients with
shock were associated with mortality rates of greater than
30% with associated correlation with the absolute lactate con-
centration [1-4]. More recently, both the presence of hyperlac-
tatemia on admission and subsequent development of
hyperlactatemia have been reported to be associated with
greater mortality in surgical ICU patients [5-7]. Also, the rapid
rate of clearance of lactate and earlier time to resolution of
hyperlactatemia have been associated with increased survival
probability [3,8,9].
APACHE: Acute Physiology and Chronic Health Evaluation; CHR: Calgary Health Region; ICU: intensive care unit; IQR: interquartile range; TISS: 
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Although it is recognized that hyperlactatemia is a common
occurrence in critically ill patients and is associated with
increased mortality, and that the resolution of hyperlactatemia
is associated with increased survival, previous studies have
focused on relatively small cohorts of selected critically ill pop-
ulations [1-3,5-7,9-12]. As a result, the occurrence, determi-
nants, and effect on outcome of hyperlactatemia in critically ill
populations at large have not been well defined. The objective
of the present study was to assess the incidence of hyperlac-
tatemia and the factors associated with it in a large population
of critically ill adult medical and surgical patients, and assess
the effect of hyperlactatemia on mortality.
Materials and methods
Study population
The patients included in the study were from a regional health
care system including the city of Calgary and surrounding
smaller cities (population 1.2 million) [13]. Critically ill adult
patients in the Calgary Health Region (CHR) are managed in
closed ICUs under the care of certified intensivists in the
Department of Critical Care Medicine, University of Calgary,
and CHR. These include a 14-bed cardiovascular surgery ICU
and three multi-system ICUs: one 24-bed multi-system ICU
that serves as the regional trauma and neurosurgical referral
center; one 14-bed multi-system ICU that is also the vascular
surgery referral center; and a 10-bed multi-system ICU. The
base study population consisted of all adults (≥ 18 years)
admitted to any multi-system or the cardiovascular surgery
ICU in the CHR between 1 January, 2003 and 31 December,
2006. The Conjoint Health Research Ethics Board at the Uni-
versity of Calgary and CHR approved this study and waived
the requirement for individual written informed consent.
Study protocol
This study utilized a retrospective cohort design. Data were
obtained using the ICU Tracer database, a regional patient
care, research, and administrative database that systematically
and uniformly records detailed demographic, clinical, labora-
tory, and hospital outcome data on all patients admitted to the
ICU in the CHR as previously described [14,15]. In CHR
ICUs, lactate is nearly always determined from venous and
arterial samples using point-of-care analysers in each of the
ICUs (Radiometer ABL-725, Radiometer Copenhagen,
Copenhagen, Denmark). In this study, any lactate measure-
ment from venous or arterial blood of more than 2 mmol/L was
deemed to represent hyperlactatemia. Patients that did not
have a lactate measurement within the first 24 hours of ICU
admission were considered to not exhibit hyperlactatemia.
Severity of illness at inception (within the first day of ICU
admission) was assessed using the Acute Physiology and
Chronic Health Evaluation (APACHE) II score [16] and inten-
sity of care using the Therapeutic Interventions Scoring Sys-
tem (TISS) [17,18].
Patients were classified into four admission categories based
on available information. Cardiac surgical patients were those
admitted to the cardiovascular surgery ICU. Trauma/neuro
patients were those patients that were victims of major trauma
as identified by the regional trauma database or had a major
admission diagnosis classification listed as either trauma and/
or neurologic; they could not be separated into distinct cate-
gories because of diagnostic coding limitations of the data-
base. Other surgical patients were those admitted directly
from the operating room, or those who were classified as hav-
ing a surgical diagnosis as defined for the APACHE II score
but excluding cardiovascular surgery, neurosurgical, and
neuro/trauma patients. Medical patients were all other
patients.
Statistical analysis
Analysis was performed using Stata version 10 (Stata Corp,
College Station, TX, USA). The cumulative incidence of hyper-
lactatemia was calculated by dividing the number of patients
with at least one episode per ICU admission episode by the
total number of ICU admission episodes. The average preva-
lence of hyperlactatemia was also calculated by dividing the
number of patient-days (or part thereof) with hyperlactatemia
by the total number of ICU admission days (or part thereof)
and reported as hyperlactatemia-days. Although all episodes
were used for cumulative incidence calculations, only each
patient's first presentation to the ICU (i.e. first episode) was
analyzed for evaluating mortality outcome. Mortality outcome
analysis was also restricted to those patients who survived for
at least one day in order to exclude those moribund at presen-
tation.
Prior to statistical analysis the underlying distribution of all con-
tinuous variables was assessed using histograms. Normally or
near-normally distributed variables were reported as means ±
standard deviations and non-normally distributed variables as
medians with interquartile ranges (IQR). Means were com-
pared using the Student's t-test. Differences in proportions
among categorical data were assessed using Fisher's exact
test for pair-wise comparisons and the chi-squared test for
multiple groups. A logistic regression model was developed to
assess the independent effects of hyperlactatemia on ICU
case-fatality. Variables included in the initial model were
APACHE II, TISS, age, gender, admission classification,
shock, and the degree of hyperlactatemia on admission. Back-
ward step-wise variable elimination was then performed to
develop the most parsimonious models.
Results
During the three-year study period, a total of 13,932 ICU
admission episodes occurred among 11,581 adult patients:
8802 (63%) were male. The median age was 63.2 (IQR =
49.7 to 73.6) years and the mean APACHE II score was 24.7
± 8.5 (n = 13,922). Of all ICU admission episodes, 4935
(35%) were classified as medical, 4395 (32%) as cardiac sur-Available online http://ccforum.com/content/13/3/R90
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gical, 2274 (16%) as other surgical, and 2328 (17%) as
trauma/neuro. Of the 8997 surgical patient admissions, 4377
(49%) were elective cases, 2690 (30%) were emergent
cases, and 1854 (21%) were not immediately post-operative.
The cumulative incidence of at least one documented episode
of hyperlactatemia during ICU admission was 5578/13,932
(40%), and the average prevalence was 20 hyperlactatemia-
days per 100 days of ICU admission. The occurrence of hyper-
lactatemia varied significantly by major admitting diagnostic
category (P < 0.001), with the highest cumulative incidence
observed among neuro/trauma patients (1053/2328; 45%),
followed by medical (2047/4935; 41%), other surgical (900/
2274; 40%), and cardiac surgical (1578/4395; 36%). The
number of hyperlactatemia-days per 100 days of ICU admis-
sion was 14.2 among neuro/trauma patients, 20.0 for medical,
20.2 for other surgical, and highest with a value of 26.1 for car-
diac surgical patients (P < 0.001). Hyperlactatemia-days was
significantly higher in patients admitted with an APACHE II
score of 25 or higher (24.9. vs. 13.1; P < 0.001), and slightly
increased in patients that were between the ages of 40 and 65
years as compared with other age ranges (21.3 as compared
with 19.5 for ages 18 to 40 years, P = 0.003; and 19.3 for
patients with age over 65 years, P < 0.001).
At presentation (within the first day of admission to the ICU)
the median lactate concentration was 1.8 (IQR = 1.2 to 2.9)
mmol/L and hyperlactatemia (lactate > 2.0 mmol/L) was iden-
tified in 5058/13,932 (36%). There was a significant relation
observed between admission class and the presence of
hyperlactatemia at presentation (P < 0.001). This was great-
est in trauma/neuro patients (972/2328; 42%), followed by
other surgical (814/2274; 36%), medical (1763/4935; 36%),
and cardiac surgical patients (1509/4395; 34%). Of the
patient admissions to the unit with hyperlactatemia (5058/
13,932) documented resolution of hyperlactatemia occurred
in 2994/5058 (59%) patients within a median time of 10.6
(IQR = 6.2 to 22.5) hours.
Among the 8874/13,932 patient admissions that did not have
hyperlactatemia at presentation, subsequent hyperlactatemia
developed in 520/8874 (6%); hyperlactatemia occurred
within a median of 2.6 (IQR = 1.5 to 5.2) days after admission.
The occurrence of this de novo hyperlactatemia in the ICU
(development of hyperlactatemia among those who did not
present with hyperlactatemia), was highest in medical patients
(284/3172; 9%) followed by other surgical (86/1460; 6%),
neuro/trauma (81/1356; 6%), and cardiac surgical (69/2886;
2%). In addition, patients with APACHE II scores of 25 or
higher, were more likely to develop de novo hyperlactatemia
(287/520; 55% P < 0.001). Moreover, patient age was also
correlated with likelihood of developing hyperlactatemia: 10%
of those aged 18 to 40 years (54/520), 36% of 40 to 65 year
olds (187/520), and 54% of those aged 65 years and older
(279/520; P < 0.001 for all). Among the 520 episodes of de
novo hyperlactatemia, nine had documented resolution to less
than 2 mmol/L within a median of 10.1 (IQR = 6.5 to 18.0)
hours, while the remainder either died (153; 29%) or were dis-
charged (358; 69%) from ICU prior to resolution.
Among the overall cohort, 1783/13,932 patients died in the
ICU. The case fatality rate among the cohort of first ICU admis-
sions for patients who survived at least the day of presentation
was 1001/9107 (11%). Among the first admission cohort with
at least one day of ICU stay, the fatality rate for those who pre-
sented with hyperlactatemia was significantly increased com-
pared with those that did not present with hyperlactatemia
(712/3634 (20%) vs. 289/5473 (5%); P < 0.001). Among
patients with hyperlactatemia at presentation, the case-fatality
rate was highest among medical (337/712; 47%), trauma/
neuro (178/712; 25%), surgical (106/712; 15%), and cardiac
surgical (91/712; 13%; P < 0.001). Of the de novo hyperlac-
tatemia patients, when considering first admissions and a day
or more of ICU stay, the case fatality was 101/379 (27%). The
case-fatality rate was highest in medical (54/101; 53%)
patients, then surgical (27/101; 27%), trauma/neuro (17/101;
17%), and cardiac surgical (3/101; 3%) patients.
After controlling for confounding variables in logistic regres-
sion analysis, increasing levels of hyperlactatemia at presenta-
tion were independently associated with increased risk for
subsequent ICU-related mortality death as shown in Table 1.
Discussion
Our study demonstrates that hyperlactatemia is common in
diverse populations of critically ill patients and that its pres-
ence at presentation or its de novo development during ICU
stay is associated with an increased risk of death.
Previous studies have investigated the impact of hyperlac-
tatemia on mortality in selected groups of patients admitted to
the ICU and have reported cumulative incidence rates of 10 to
70% [1-7]. The observation that hyperlactatemia is associated
with increased risk for death is not new [1,12]. Studies of crit-
ically ill medical [3,19,20] and surgical [9,11,21,22] patients
have shown an association between elevated lactate with pro-
longed clearance and mortality. These rates have varied signif-
icantly partly based on the degree of mortality being related to
factors such as the degree of hyperlactatemia and time to its
clearance [3,9,11]. These studies have typically been limited
by small size (hundreds of patients). However, no previous
study has simultaneously assessed the incidence of hyperlac-
tatemia in a large mixed cohort consisting of medical and sur-
gical patients. Our data is important because we show that
certain patient groups are at increased risk of mortality in the
setting of hyperlactatemia.
Our study adds to the existing literature in the following ways.
First, we directly assess medical, surgical, and neuro/trauma
patients; previous studies have only looked at single popula-Critical Care    Vol 13 No 3    Khosravani et al.
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tions and therefore the effect of diagnostic class is not directly
comparable. Second, our findings demonstrate a stepwise
relation between elevated lactate levels and an increasing
degree of risk. Finally, although a number of previous studies
have been powered to look at crude mortality associated with
elevated lactate levels, few have been able to assess multiple
confounders using logistic regression. Our study examines the
largest cohort to date and had adequate power to analyze for
multivariable confounders for mortality.
In several studies different cut-offs for lactate concentration
were used (e.g. > 5 mmol/L) [1,2,4,5] and there appears to be
a relation with increasing level and increased risk for death.
Our data suggests that use of a single cut-off level for hyper-
lactatemia can result in loss of point-wise discrimination that
appears to risk stratify the patients as observed in our cohort.
It is important to note that we observed that elevated lactate at
admission adds to the prediction of subsequent mortality by
APACHE II score.
Although our study has several strengths related to large size
and inclusion of a broad range of patients, there are a number
of limitations that merit discussion. We did not assess lactate
based on an algorithm but rather based on physician-depend-
ent indications and lactate measurement was ordered as
required. Therefore, we may have missed relevant cases. How-
ever, it is conceivable that the majority of such cases would be
detected on routine lactate measurement as part of arterial
blood gas analysis in critically ill patients. In addition, it is con-
ceivable that in some patients hyperlactatemia was a transient
event (such as with seizures), with resolution without conse-
quence. However, such factors would bias toward a null result,
and thus our findings are likely to be conservative.
We did not collect or analyze detailed clinical data and as such
were not able to define the most likely clinical etiology of the
hyperlactatemia. It has been suggested that the underlying
cause for the hyperlactatemia, specifically the nature of the
acid-base disturbance and whether a base-deficit exists may
influence the predictive ability of lactate measurements [23]. In
particular, the presence of a primary metabolic acidosis is
highly predictive of mortality [10]. In addition, the underlying
diagnosis and medical treatment can also influence the predic-
tive capacity of lactate measurements, such as in HIV-infected
patients [24,25]. Moreover, in our study most lactate measure-
ments were obtained using the same device model of point-of-
care analyzers, with the majority of samples being arterial and
a small proportion being sent to a central laboratory. However,
this is not likely to be a major bias as a recent study compared
measurement techniques using a hand-held lactate analyzer
and a bench-top blood gas analyzer to a central laboratory and
found them to be in good agreement [26]. In the case of
venous sampling we did not record whether they were
obtained from central or peripheral sites. In quantifying hyper-
lactatemia-days, we assumed that where no sample was
tested hyperlactemia was not present, and therefore the true
rate may have been underestimated. A final limitation is that we
Table 1
Logistic regression modeling of presenting factors associated with death in the intensive care unit
OR 95% CI
TISS (per point) 1.02 1.02 to 1.03
APACHE II (per point) 1.08 1.07 to 1.09
Age 1.02 1.02 to 1.03
Lactate concentration (max on day of admission, reference 0 to 2 mmol/L) 1
2 to 5 mmol/L 1.94 1.62 to 2.32
5 to 10 mmol/L 3.38 2.64 to 4.33
10 to 15 mmol/L 4.41 2.99 to 6.50
15 to 20 mmol/L 7.58 3.93 to 14.60
20-max mmol/L 10.89 4.85 to 24.48
Admission classification medical (reference) 1
Cardiac surgical 0.08 0.06 to 0.11
Other surgical 0.48 0.38 to 0.60
Trauma/Neuro 1.64 1.35 to 2.01
The final model (n = 9036; among the total number of 9107 subjects data for TISS and APACHE II were only available for 9036 and 9100 cases, 
respectively) had good discrimination (area under the receiver operator characteristic curve = 0.852) and calibration (Hosmer-Lemeshow 
goodness of fit test = 1.0)
APACHE = Acute Physiology and Chronic Health Evaluation; CI = confidence interval; OR = odds ratio; TISS = Therapeutic Interventions 
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did not look at goal-directed interventions that were employed
to correct lactate levels [27].
Conclusions
In summary, we demonstrate that hyperlactatemia is common
and associated with adverse outcome. Inclusion of hyperlac-
tatemia adds to the prediction ability of the existing APACHE
II score. Moreover, we defined and compared the admission
and de novo development of hyperlactatemia directly between
different patient groups, showing that diagnostic class and
absolute level of lactate elevation are important parameters.
Our data suggests that there is predictive merit in routine
measurement of lactate at presentation to the ICU. These find-
ings may be useful to administrators and may allow for more
accurate adjustment of mortality risk for benchmarking pur-
poses. Similarly, clinicians can use elevated lactate levels to
identify patients for potentially targeted monitoring and inter-
vention.
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